REVIEW article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1593157
This article is part of the Research TopicAdvancements in targeted therapies for genitourinary cancersView all 3 articles
Mechanism of action of HMGB1 in urologic malignancies
Provisionally accepted
- 1Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China
- 2Zunyi Medical University, Zunyi, Guizhou Province, China
- 3Department of Urology, Third Affiliated Hospital of Zunyi Medical University, Zunyi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
High mobility group protein 1 (HMGB1) is a highly conserved chromatin-associated protein that is widely found in eukaryotic cells. Studies have shown that HMGB1 plays an important role in the development and progression of urological malignancies. As a classical damage-associated molecular pattern (DAMP), HMGB1 usually acts as a DNA chaperone in the nucleus. In response to external stimuli, HMGB1 is actively secreted by immune cells and can also be passively released into the extracellular space from necrotic cells. By interacting with various signaling pathways and receptors, HMGB1 can induce immune system activation and participate in carcinogenesis, metastasis and angiogenesis. This review systematically summarizes the role of recent research progress of HMGB1 in carcinogenesis, progression, prognosis and potential clinical applications of different urological malignancies, providing reference for the diagnosis and treatment of urological malignancies.
Keywords: High mobility group protein 1 (HMGB1), prostate cancer, Renal cell carcinoma, urologic tumors, Bladder cancer
Received: 13 Mar 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Li, Lei, Lanlan, Fu, Chen and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaorong Yang, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.